Intersect ENT (NASDAQ: XENT) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare Intersect ENT to similar businesses based on the strength of its institutional ownership, earnings, profitability, risk, dividends, valuation and analyst recommendations.
Earnings and Valuation
This table compares Intersect ENT and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Intersect ENT||$87.16 million||-$19.71 million||-42.36|
|Intersect ENT Competitors||$827.23 million||$159.50 million||72.35|
Intersect ENT’s rivals have higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
83.1% of Intersect ENT shares are held by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 13.7% of Intersect ENT shares are held by insiders. Comparatively, 11.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Intersect ENT and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intersect ENT Competitors||-126.42%||-36.27%||-9.90%|
This is a summary of current recommendations for Intersect ENT and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intersect ENT Competitors||181||1151||2516||90||2.64|
Intersect ENT presently has a consensus target price of $27.11, suggesting a potential downside of 8.56%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.94%. Given Intersect ENT’s rivals higher probable upside, analysts plainly believe Intersect ENT has less favorable growth aspects than its rivals.
Risk & Volatility
Intersect ENT has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Intersect ENT’s rivals have a beta of 1.02, indicating that their average stock price is 2% more volatile than the S&P 500.
About Intersect ENT
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
What are top analysts saying about Intersect ENT Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT Inc. and related companies.